JP5707131B2 - 抗炎症性化合物とその用途 - Google Patents

抗炎症性化合物とその用途 Download PDF

Info

Publication number
JP5707131B2
JP5707131B2 JP2010520344A JP2010520344A JP5707131B2 JP 5707131 B2 JP5707131 B2 JP 5707131B2 JP 2010520344 A JP2010520344 A JP 2010520344A JP 2010520344 A JP2010520344 A JP 2010520344A JP 5707131 B2 JP5707131 B2 JP 5707131B2
Authority
JP
Japan
Prior art keywords
sulindac
compounds
cancer
phospho
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010520344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535817A5 (https=
JP2010535817A (ja
Inventor
リーガス，バジル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010535817A publication Critical patent/JP2010535817A/ja
Publication of JP2010535817A5 publication Critical patent/JP2010535817A5/ja
Application granted granted Critical
Publication of JP5707131B2 publication Critical patent/JP5707131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010520344A 2007-08-10 2008-08-11 抗炎症性化合物とその用途 Active JP5707131B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95525807P 2007-08-10 2007-08-10
US60/955,258 2007-08-10
US98958407P 2007-11-21 2007-11-21
US60/989,584 2007-11-21
PCT/US2008/072788 WO2009023631A1 (en) 2007-08-10 2008-08-11 Anti-inflammatory compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014015731A Division JP2014111627A (ja) 2007-08-10 2014-01-30 抗炎症性化合物とその用途

Publications (3)

Publication Number Publication Date
JP2010535817A JP2010535817A (ja) 2010-11-25
JP2010535817A5 JP2010535817A5 (https=) 2011-09-22
JP5707131B2 true JP5707131B2 (ja) 2015-04-22

Family

ID=40351107

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520344A Active JP5707131B2 (ja) 2007-08-10 2008-08-11 抗炎症性化合物とその用途
JP2014015731A Withdrawn JP2014111627A (ja) 2007-08-10 2014-01-30 抗炎症性化合物とその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014015731A Withdrawn JP2014111627A (ja) 2007-08-10 2014-01-30 抗炎症性化合物とその用途

Country Status (10)

Country Link
US (6) US8236820B2 (https=)
EP (1) EP2180788B1 (https=)
JP (2) JP5707131B2 (https=)
CN (1) CN101820755B (https=)
AU (1) AU2008286954B2 (https=)
CA (1) CA2705463C (https=)
ES (1) ES2618482T3 (https=)
IN (1) IN2010KN00853A (https=)
PL (1) PL2180788T3 (https=)
WO (1) WO2009023631A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094589A1 (en) * 2010-01-29 2011-08-04 Basil Rigas Nonsteroidal antiinflammatory derivatives with decreased toxicity and methods of use
WO2011133385A2 (en) * 2010-04-16 2011-10-27 The Research Foundation Of State University Of New York Novel ether-based compounds and their use
CN103827310B (zh) * 2011-07-14 2017-09-22 财团法人国家卫生研究院 Map4k3作为自体免疫疾病、癌症、发炎及il‑17相关疾病的生物标记及治疗标的
WO2013130625A1 (en) * 2012-02-27 2013-09-06 Basil Rigas Phospho-ester derivatives and uses thereof
US9402821B2 (en) 2012-08-13 2016-08-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
US20140088044A1 (en) * 2012-09-21 2014-03-27 Basil Rigas Product comprising a nicotine-containing material and an anti-cancer agent
EP2711006A1 (en) 2012-09-21 2014-03-26 Basil Rigas Product Comprising a Nicotine-Containing Material and an Anti-Cancer Agent
EP2897621A4 (en) * 2012-09-21 2016-08-10 Basil Rigas COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
MX2015006715A (es) 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
US10023555B2 (en) 2013-02-07 2018-07-17 Research Foundation Of The City University Of New York NSAIDs derivatives and uses thereof
RU2720180C2 (ru) 2013-09-24 2020-04-27 Универзитет Цу Кельн Соединения, применяемые в лечении неопластических заболеваний
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015148649A2 (en) * 2014-03-26 2015-10-01 Basil Rigas Systems and methods for ameliorating the effects of tobacco products
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
HUE062406T2 (hu) 2016-09-28 2023-10-28 Medicon Pharmaceuticals Inc Készítmények szemészeti állapotok kezelésére
CN109121393B (zh) * 2017-02-24 2021-11-30 拉芳家化股份有限公司 一种抗炎乳液
JP2020536067A (ja) * 2017-09-28 2020-12-10 メディコン ファーマシューティカルズ，インコーポレイテッド 眼の状態を処置するための組成物および方法
CN117417281A (zh) * 2017-09-28 2024-01-19 麦迪康制药公司 抗炎、抗癌和抗血管生成化合物，药物组合物及其制备和使用方法
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
TWI679279B (zh) * 2018-05-09 2019-12-11 臺中榮民總醫院 檢測成人發作型史笛兒氏症之罹病風險及預後之方法
EP4272826A3 (en) 2021-05-24 2024-01-17 Medicon Pharmaceuticals, Inc. Treating pain associated with diabetic peripheral neuropathy
JP2024520463A (ja) 2021-05-24 2024-05-24 メディコン ファーマシューティカルズ，インコーポレイテッド 化学療法誘発性末梢神経障害に関連する疼痛の処置
MD4522143T2 (ro) 2022-11-23 2025-11-30 Medicon Pharmaceuticals Inc Tratamentul durerii asociate cu sensibilizare centrală
WO2025106974A1 (en) * 2023-11-17 2025-05-22 The Board Of Trustees Of The Leland Stanford Junior University Prodrug moieties and compounds comprising the same
WO2025111079A1 (en) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomers of phosphosulindac

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3396193A (en) * 1965-07-01 1968-08-06 Us Vitamin Pharm Corp Halogenated cis-cinnamic acids
US4006204A (en) * 1975-04-30 1977-02-01 Nelson Research & Development Company Phosphoric acid diesters
DE3219821A1 (de) * 1982-05-26 1983-12-01 Bayer Ag, 5090 Leverkusen Substituierte diphenylether, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPS60101993A (ja) * 1983-11-08 1985-06-06 日立化成工業株式会社 印刷配線板の製造法
JPS60146855A (ja) * 1984-01-11 1985-08-02 Ono Pharmaceut Co Ltd アニリン誘導体
JPS62184458A (ja) * 1986-02-08 1987-08-12 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
US4888328A (en) 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
JPH07261315A (ja) * 1994-03-23 1995-10-13 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料および画像形成方法
IT1270996B (it) 1994-07-22 1997-05-26 Wilton Licensing Ag Derivati fosforilati di composti aventi attivita' antiinfiammatoria o analgesica e procedimento per la loro preparazione
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
IT1307928B1 (it) 1999-01-26 2001-11-29 Nicox Sa Metodo di sintesi di nitrossimetilfenil esteri di derivatidell'aspirina.
IL137672A0 (en) * 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US20030060465A1 (en) * 2000-12-19 2003-03-27 Jilani Jamal A. Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds
AU2002226225B2 (en) * 2001-01-18 2008-03-20 Dermavant Sciences GmbH Novel 1,2-diphenylethene derivatives for treatment of immune diseases
ITMI20010985A1 (it) 2001-05-15 2002-11-15 Nicox Sa Farmaci per il morbo di alzheimer
DE20110355U1 (de) 2001-06-22 2001-08-30 Wella Ag, 64295 Darmstadt (Dihydroxyphenyl)-acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel
ITMI20011744A1 (it) 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
ITMI20020773A1 (it) 2002-04-11 2003-10-13 Nicox Sa Farmaci per il trattamento dell'artrite
WO2005065361A2 (en) 2003-12-31 2005-07-21 Khosrow Kashfi Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
KR100839016B1 (ko) 2006-12-27 2008-06-17 (주)네오팜 세라마이드 유도체 및 그 제조방법과 이를 포함하는 아토피 피부염 치료제

Also Published As

Publication number Publication date
AU2008286954B2 (en) 2015-01-15
PL2180788T3 (pl) 2017-06-30
AU2008286954A1 (en) 2009-02-19
US20160243137A1 (en) 2016-08-25
US20220409638A1 (en) 2022-12-29
CN101820755A (zh) 2010-09-01
HK1147912A1 (en) 2011-08-26
WO2009023631A1 (en) 2009-02-19
ES2618482T3 (es) 2017-06-21
EP2180788B1 (en) 2016-12-21
CA2705463A1 (en) 2009-02-19
US20190307780A1 (en) 2019-10-10
IN2010KN00853A (https=) 2015-08-28
US20090099137A1 (en) 2009-04-16
EP2180788A1 (en) 2010-05-05
US20120316139A1 (en) 2012-12-13
US20200237787A1 (en) 2020-07-30
CA2705463C (en) 2014-10-07
JP2014111627A (ja) 2014-06-19
JP2010535817A (ja) 2010-11-25
CN101820755B (zh) 2013-05-15
CA2705463E (en) 2009-02-19
EP2180788A4 (en) 2011-08-24
US8236820B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
JP5707131B2 (ja) 抗炎症性化合物とその用途
KR101698028B1 (ko) 수용성 아세트아미노펜 유사체
JP6000122B2 (ja) トリプトリド製品
US7585997B2 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
JP6442615B2 (ja) インドール酢酸コア構造を含む化合物とその応用
JP5529280B2 (ja) 癌治療用のジ（フェニルプロパノイド）・グリセロール誘導体
JP2002518506A (ja) アリールスルホンアニリドホスフェート
WO2016168118A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
HK1147912B (en) Anti-inflammatory compounds and uses thereof
US20140121185A1 (en) Compounds and compositions for use in the treatment and prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever
CN113461528B (zh) 一种苯氧酸类衍生物及其应用
JP5324921B2 (ja) 抗癌剤としてのデメチルペンクロメジン類似体とその使用
WO2011094589A1 (en) Nonsteroidal antiinflammatory derivatives with decreased toxicity and methods of use
CN101255117A (zh) 带一氧化氮供体的非甾体类抗炎药前体药物及其制备方法
WO2007060976A1 (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物
CA2076050A1 (en) Branched alkyl esters of 4-bis (chloroethyl) aminophenyl-alkyl carboxylic acids for treatment of primary and metastatic tumors of the lymphatic system, and of cancers of the breastand ovaries
HK1137426B (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
HK1137426A1 (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131024

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140130

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140130

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150302

R150 Certificate of patent or registration of utility model

Ref document number: 5707131

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250